Ridgefield, Conn., November 13, 2017 – Boehringer Ingelheim today announced results from two new analyses of the phase III RE-VERSE AD™ study, which evaluated the safety and efficacy of idarucizumab, ...
A Pradaxa ad featuring the fish illustration.--Courtesy of Boehringer Ingelheim What do fish and atrial fibrillation have in common? AFib feels like a fish fluttering in your chest, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results